Table VI.
Effects of anticoagulation on LE-DVT biomarker levels
| Biomarker |
No prophylactic
anticoagulation (95% CI) |
Prophylactic
anticoagulation (95% CI) |
Therapeutic
anticoagulation |
P valuea |
|---|---|---|---|---|
| Number of patients | 95 | 17 | 5 | |
| Soluble P-selectin, ng/mL | 77.3 (70.2-84.5) | 76.6 (58.6-94.7) | 44.6 | .94 |
| D-dimer, ng/L | 5.50 (4.65-6.35) | 6.62 (4.63-8.62) | 0.99 | .29 |
| C-reactive protein, μg/mL | 4.98 (3.78-6.17) | 7.03 (2.85-11.22) | 7.13 | .33 |
| von Willebrand factor (% activity) | 158.5 (133.4-162.3) | 183.5 (129.0-211.0) | 179 | .31 |
| ADAMTS-13 (% activity) | 92 (87-96) | 85 (70-101) | .42 | |
| Wells score | 2.91 (2.62-3.19) | 2.71 (2.14-3.27) | .52 | |
| Body mass index | 29.9 (28.4-31.4) | 32.0 (26.7-37.2) | .43 | |
| Caprini score | 6.0 (5.5-6.5) | 8.1 (6.5-9.7) | .01 |
ADAMTS-13, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; CI, confidence interval; DVT, deep venous thrombosis; LE, lower extremity.
a
Comparison between patients on prophylactic anticoagulation and patients on no prophylactic or therapeutic anticoagulation.